Kodiak Sciences Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $182.4M | $126.1M | $206.3M | $267.6M | $217.3M |
| Operating expenses | $234.4M | $186.8M | $277.3M | $341.4M | $267.1M |
| Operating income | -$234.4M | -$186.8M | -$277.3M | -$341.4M | -$267.1M |
| Interest expense | $0 | $0 | $13,000 | $18,000 | $47,000 |
| Pretax income | -$229.9M | -$176.2M | -$260.4M | -$333.8M | -$266.9M |
| Income tax expense | $52,000 | $20,000 | $33,000 | $33,000 | $74,000 |
| Net income | -$230.0M | -$176.2M | -$260.5M | -$333.8M | -$267.0M |
| Balance Sheet | |||||
| Cash and equivalents | $209.9M | $168.1M | $285.5M | $190.4M | $731.5M |
| Current assets | $214.8M | $171.9M | $289.3M | $486.0M | $734.8M |
| Total assets | $351.5M | $335.6M | $479.4M | $666.6M | $904.2M |
| Current liabilities | $45.5M | $25.6M | $41.7M | $52.5M | $64.7M |
| Total liabilities | $194.2M | $185.3M | $213.6M | $230.5M | $240.9M |
| Stockholders' equity | $157.4M | $150.3M | $265.8M | $436.2M | $663.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$136.0M | -$117.3M | -$154.2M | -$206.5M | -$182.3M |
| Depreciation and amortization | $18.3M | $18.7M | $18.3M | $3.8M | $1.0M |
| Stock-based compensation | $58.9M | $60.2M | $88.6M | $106.0M | $61.4M |
| Capital expenditure | $506,000 | $375,000 | $41.4M | $37.0M | $17.0M |
| Free cash flow | -$136.5M | -$117.7M | -$195.5M | -$243.5M | -$199.3M |
| Impairments | — | $0 | $0 | $0 | $0 |
Shares outstanding 62.6M · Free float 63.0%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.